370 results about "Intestinal tract diseases" patented technology

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

The invention relates to a controlled-release colon targeting drug adminitration preparation. The forms of the preparation are colon site-specific coated tablets or colon targeting pellets. The preparation consists of a tablet core or pellet core, an isolating layer and a controlled-release coating layer, wherein the controlled-release coating layer comprises an internal coating layer and an external coating layer. By adopting the multilayer coating technology, enteric soluble acrylic resin water dispersion and osmotic acrylic resin water dispersion are used as main coating materials for carrying out coating, thereby obtaining the controlled-release colon targeting drug adminitration preparation. The preparation of the invention enables drugs to be released at a constant rate at a colon section, realizes accurate site-specific drug release, increases the concentration of the drugs at some parts of positions with pathological changes, is beneficial to treating ulcerative colitis and carcinoma of colon, avoids the stimulation of the drugs on stomaches and small intestines, achieves the goal of colon site-specific drug release, enhances the targeting site-specific curative effect on colon diseases and reduces the toxic and side effect. Compared with the common oral preparations, under the condition of the same drug adminitration dosage, the preparation of the invention can enhance the curative effect and reduce the incidence rate of untoward reactions. Compared with the enemas or the rectal suppositories, the preparation has the advantages of uniform drug distribution in the colon and good patient compliance.

The invention discloses a rosa roxburghii polysaccharide, as well as a preparation method and application thereof. The preparation method mainly comprises raw material pretreatment, extraction, deproteinization, de-coloration, alcohol precipitation, as well as separation and purification, wherein the extraction is to mix pretreated rosa roxburghii dry powder and water in a mass volume ratio of (1to 15) to (1 to 35), and perform extraction at a temperature of 55 to 95 DEG C; perform centrifugal separation to obtain a rosa roxburghii polysaccharide extracting solution, and concentrate the rosaroxburghii polysaccharide extracting solution under reduced pressure to 1 / 3 to 1 / 6 of the original volume to obtain a concentrated solution of the rosa roxburghii polysaccharide. The rosa roxburghii polysaccharide prepared by the invention has the advantages of high purity and uniform molecular weight. Compared with the existing rosa roxburghii polysaccharide, as proved by in-vitro fermentation experiments, the rosa roxburghii polysaccharide disclosed by the invention can promote the generation of short-chain fatty acids such as acetic acid, propionic acid and butyric acid, promote the growthof beneficial bacteria such as lactic acid bacteria and bifidobacterium, and can be taken as prebiotics. Meanwhile, the rosa roxburghii polysaccharide can inhibit the activity of alpha-glucosidase, and can be applied to healthy foods or medicines having auxiliary therapy effects on intestinal diseases and diabetes mellitus.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

The invention discloses sweets rich in dietary fibers and a preparation method of the sweets. The sweets rich in dietary fibers disclosed by the invention are made from the following substances in parts by weight: 40-70 parts of water soluble dietary fibers, 5-15 parts of resistant starch, 5-10 parts of sugar alcohol, 10-20 parts of white granulated sugar and 0.5-2 parts of soybean lecithin. The sweets rich in dietary fibers, disclosed by the invention, contain many dietary fibers and little sugar and little fat, are good in mouth feel, are convenient to eat, and can improve the function of intestinal tracts and reduce adverse impact caused by high sugar and high fat in the sweets. The preparation method of the sweets rich in dietary fibers disclosed by the invention is simple, and the prepared sweets have the effects of loosening the bowel to relieve constipation, regulating blood sugar and blood fat, reducing cholesterol, improving the function of the intestinal tracts and controlling weight, are beneficial to the physical health of people, and are extremely suitable for crowds suffering from high blood pressure, high blood fat, high cholesterol, diabetes, obesity, constipation, intestinal tract diseases and the like to eat.

The invention relates to a traditional Chinese medicinal composition for treating gastrointestinal tract, in particular to a medicinal composition for treating gastrointestinal tract diseases such as acute and chronic gastritis, enteritis, gastric ulcer, superficial gastritis, gastric acid, gastrectasia, indigestion and the like. The invention also relates to a preparation of the medicinal composition. The traditional Chinese medicinal composition for treating gastrointestinal tract comprises the medicaments in percentage by weight: 10-25 parts of red ginseng, 10-23 parts of poria, 8-20 parts of bighead atractylodes rhizome, 10-25 parts of rhizoma ligustici wallichii, 10-25 parts of rhizoma atractylodis, 10-25 parts of cyperus rotundus, 10-25 parts of medicated leaven, 10-25 parts of gardenia, 10-23 parts of betelnut, 8-20 parts of radix aucklandiae, 5-15 parts of liquorice, 5-8 parts of malt and 10-25 parts of hawthorn. The medicinal composition for treating the gastrointestinal tract is orally taken and has the efficacies of regulating the flow of qi, comforting the stomach, diminishing inflammation, killing pain, repairing gastrointestinal mucosa and ulceration, enhancing gastrointestinal motility, adjusting gastric acid secretion, promoting digestive absorption and the like.

The invention discloses a new microbial feed additive, a preparation method thereof, and the application in the animal and plant breeding. The feed additive is mainly composed of the following components with the parts by weight: 20 to 40 shares of Boas-Oppler bacillus, 20 to 40 shares of Saccharomyces cerevisiae, and 30 to 60 shares of Bacillus subtilis. The feed additive of the invention is rich in active ingredients including lactic acid, digestive ferment, amino acid, protein, vitamin, nutrilit, etc., and has the efficacy on the following aspects: 1. the autoimmunity of animals and poultries is improved, the disease rate of intestinal tract disease is reduced, and the mortality rate is lowered; 2. the production performance of the animals is improved; 3. the feed percent conversion is improved, the ratio of feed-meat, feed-egg, and the feed-milk is lowered; 4. the milk producing and egg-laying time of the animals and the poultries is prolonged, the outside and inside quality of the products of the animals and the poultries is improved, the content of cholesterol and fat is lowered, and the pesticide residue is deteriorated; 5. the odour of dejection of the animals and the poultries is eliminated, the shit and urine pollution in a breeding farm is lowered, the quantity of mosquito and fly is reduced, and the production condition is improved.

The invention provides a method for preparing a fermented feed for sheep. The fermented feed is synthesized from corn, soybean meal, bran, calcium hydrogen phosphate, rice bran, rapeseed meal, pomace, grass meal, trace elements, vitamins, salt and beneficial microbial floras. The method comprises the following steps of removing impurities according to a reasonable ratio and mixing and stirring the materials, thus preparing the fermented feed. The fermented feed is sealed with plastic bag films and is packaged, warehoused, sold or reserved. The fermented feed for sheep can change odors in sheep houses, purify the environment and simultaneously save cost, is low in price, adopts raw materials extremely easily purchased, can turn waste into wealth and bring obvious economic and social benefits, is natural, green, ecological and environment-friendly and has an obvious function of preventing intestinal diseases of sheep.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and / or -8 mediated antiport of sodium and / or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and / or salt present in the GI tract.

The invention discloses a Chinese medicinal herb disease-resistant additive for a prawn feed. The additive is prepared from the following raw materials in parts by weight: 20-30 parts of indigowoad root, 10-20 parts of parslane herb, 10-20 parts of dangshen, 10-20 parts of garlic, 10-15 parts of baical skullcap root, 10-15 parts of largehead atractylodes rhizome, 10-15 parts of Chinese pulsatillaroot and 8-12 parts of dried orange peel. The additive is prepared by the following steps of: grinding the Chinese medicinal herbs into fine powder of 100 meshes; and mixing uniformly. The invention has the advantages: (1) the adding amount of the feed additive in a prawn compound feed is only 0.15-0.25 percent, and the additive can be fed after being mixed with the feed in the weight ratio 1:500before feeding; (2) the immunity and disease resistance of prawns can be enhanced remarkably, the survival rate is increased, a good disease resistance effect on intestinal tract diseases such as prawn enteritis and the like is particularly achieved, and intestinal mucosa injury is repaired; (3) the additive does not cause any adverse effect on the palatability of the prawn compound feed; and (4)raw materials adopted for the additive have rich sources in China and stable and low prices, and the production and processing processes are simple.

A medicine in the form of capsule for treating enterogastric diseases is disclosed, whose main active component is 1,4-dimethyl-7-isopropyl-3-sodium azulenylsulfonate. Its advantages are high curative effect, and easy desintegration and absorption.